Business Wire

MEDSCAPE

14.2.2024 09:01:27 CET | Business Wire | Press release

Share
Medscape Global Launches Innovative Programmatic Offering Setting a New Standard in Targeted HCP Engagement in the United Kingdom, European Union and Canada

Medscape, the leading provider of healthcare information globally, and PulsePoint, which offers a marketing technology platform, are integrating their capabilities to introduce Medscape Extend. For the first time ever, this innovative solution empowers marketers to accurately reach and message verified healthcare professionals (HCPs) across the internet in the UK, EU, and Canada. With Medscape Extend, Medscape has integrated its highly engaged and authenticated HCP membership with PulsePoint's programmatic targeting capabilities into a single platform that enables the delivery of advertising to HCPs across all digital media touchpoints.

“The global pharma media industry is in a period of positive transformation, with publishers, agencies and clients pushing for increasingly intelligent approaches to prescription brand challenges. Medscape Extend is a brilliant addition to this and opens the door to creative media campaigns both on and off the Medscape Professional Network,” said Richard Springham, Managing Director, Initiative Health. “The ability to target verified HCPs in a multi-dimensional manner across their entire media journey is a key facet of modern HCP media campaigns. The team at Medscape have been able to build this in a connected, compliant, and scalable way. I’m excited to see how planners across the industry use Medscape Extend creatively in campaigns.”

In the ever-evolving landscape of pharmaceutical marketing, reaching healthcare professionals with targeted and relevant content wherever they engage is crucial. One powerful tool in the arsenal of global pharma marketers remains messaging HCPs on endemic sites like the Medscape Everywhere network. However, with Medscape Extend, marketers can now extend this marketing strategy across the open internet and in a manner that is fully compliant against the necessary European General Data Protection Regulation (GDPR) consent.

“With this launch, we’re excited to continue delivering the market high quality audiences, with scale, transparency, and real-time optimization. There's a huge upside for advertisers who are looking to reach healthcare professionals in Europe and Canada,” said Jeremy Schneider, Group General Manager of WebMD Global. “Medscape Extend represents our commitment to innovation in advertising. As technology has evolved and data capabilities have gotten more precise, advertisers are demanding greater targeting sophistication and automated technologies in addition to the value of direct media.”

Key Benefits for Pharma Marketers:

  • Unrivaled reach: Greater reach, scale and opportunity to accurately engage HCPs throughout their journey starting on Medscape, and across the open Internet via PulsePoint’s technology
  • Unprecedented insights: Enhanced signals from Medscape 1st party HCP profiles combined with PulsePoint contextual data
  • GDPR Compliance through Medscape's Verification Process: Active opt-in 1st party consent data from Medscape’s Global Network properties

Initially, Medscape Extend will be used to deliver relevant unbranded content to healthcare professionals in the United Kingdom, European Union and Canada. As part of WebMD Health Corporation, a Internet Brands company, Medscape and PulsePoint already work together in the U.S. to deliver similar healthcare professional digital marketing solutions.

About Medscape

Medscape is the leading source of clinical news, health information, and point-of-care tools for health care professionals. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools. Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses and other educational programs for physicians, nurses, and other health care professionals.

Both Medscape and Medscape Education are part of WebMD Health Corp., an Internet Brands company, which is part of the KKR portfolio.

About PulsePoint

PulsePoint is a leading technology company that uses real-world data in real time to optimize campaign performance and revolutionize health decision-making. Leveraging proprietary datasets and methodology, PulsePoint targets healthcare professionals and patients with an unprecedented level of accuracy—delivering unparalleled results to the clients we serve. The company is also part of Internet Brands. For more information, visit pulsepoint.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240214448771/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years27.2.2026 07:00:00 CET | Press release

Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of life1 These results, to be presented at 2026 Winter Clinical™ Miami, mark the longest LTE study in prurigo nodularis reported to date1 Nemluvio is the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis2-5 Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the United States (U.S.) and European Union (EU)4,5 Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed

Venture Global Announces New Long-Term LNG Partnership with Hanwha of Korea27.2.2026 01:00:00 CET | Press release

20-year sales and purchase agreement marks Venture Global’s first SPA with a Korean entity Today, Venture Global, Inc. (NYSE: VG) and Hanwha Aerospace Co., Ltd. announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 1.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement brings Venture Global’s long-term contracted portfolio to over 46 MTPA. “Venture Global is thrilled to announce our first long-term supply deal in Korea through a new partnership with Hanwha Aerospace which marks another important step in expanding reliable, long-term LNG supply to our partners in Asia,” said Mike Sabel, CEO of Venture Global. “We are proud to support growing global energy needs with low-cost, secure American LNG while strengthening the strategic energy partnership between the United States and South Korea to support long-term industrial and economic growth.” About Venture Global Ventu

Hydnum Steel Secures 500 MW of Electrical Power, a Key Step Forward in the Construction of Its Clean Steel Plant in Spain27.2.2026 00:00:00 CET | Press release

The company will produce flat steel, a product for which the EU has an annual deficit of almost 11 million tons Hydnum Steel has taken a decisive step towards constructing Spain’s first clean steel plant after being granted access to the electricity grid at the Brazatortas node in the province of Ciudad Real. The company has been granted an electricity capacity of 500 MW, as published in the Official State Gazette, which should be enough to guarantee supply to its electric arc furnace. This concession marks a significant milestone for a pioneering project in the Iberian Peninsula. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225309290/en/ Image recreating the steel plant that Hydnum Steel will build in Puertollano, Spain Hydnum Steel is consolidating its position as a reliable supplier of clean European steel. The fully digitally integrated plant will produce hot-rolled steel coils efficiently and sustainably, with bene

1089 Inc. Partners with Price Forbes and Oka-Lloyd's Syndicate 1922 to Launch Market-Defining First: Carbon Asset Insurance Framework for Transportation and Energy Sectors26.2.2026 23:01:00 CET | Press release

New program introduces dedicated insurance safeguards and immutable transfer infrastructure to advance fiscal maturation of global carbon markets, enabling scaled participation across world's highest-emitting sectors, Transportation and Energy. 1089 Inc., in collaboration with Price Forbes and Oka, The Carbon Insurance Company, announce launch of an insured carbon asset designed to bring institutional safeguards, disciplined financial architecture, and verifiable data integrity to carbon markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226012782/en/ 1089 Inc. is Advancing Carbon™, focused on evolving global carbon markets and decarbonizing the highest-emitting sectors on the planet: Transportation and Energy. The framework provides defined risk coverage for 1089’s CX89 Advanced Fuels Carbon Assets, underwritten by Lloyd’s Syndicate 1922 and placed with the support of Price Forbes and Oka. The program introduces ins

Sun Nuclear QADS 2026 Event Combines Clinical Insight and New Innovations for Advancing Radiation Therapy QA26.2.2026 23:00:00 CET | Press release

15th QA & Dosimetry Symposium convenes medical physics and radiation therapy community in RomeTwo days of sessions span diverse topics from 24 clinical practitioners and thought leadersEvent introduces new Daily QA™ 4 Pro device and features expansion of AI-enabled solutions Sun Nuclear, a Mirion Medical company, today opened the QA & Dosimetry Symposium (QADS), taking place over the next two days in Rome, Italy. The 15th installment brings together more than 230 clinical physicists and radiation medicine professionals from nearly 40 countries. Participants from diverse clinical environments will earn continuing education credits while sharing practical insights, emerging approaches, and real-world experiences shaping the future of quality and patient safety in cancer care. Building on its legacy as a peer-driven forum with practical applications, QADS 2026 features sessions delivered by 24 speakers spanning: Future Directions in Machine and Patient QA and In-vivo Dosimetry Stereotacti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye